Ligand Pharmaceuticals Inc LGND announced it has entered into a worldwide license agreement with drug discovery company xCella Biosciences Inc under which xCella will use the former s OmniAb platform for the discovery of fully human mono and bispecific antibodies Note that OmniAb
June 01, 2017 at 04:03AM
from
No comments:
Post a Comment